You searched for "Stone"
Transurethral enucleation is superior to resection for the management of LUTS secondary to BPH
This meta-analysis (Level 1b evidence) examined the efficacy and safety of two primary transurethral therapies used in the management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), enucleation (HoLEP – holmium laser enucleation of prostate, ThuLEP,...
Male LUTS: where do we stand?
Patients’ preferences and expectations depend on cultural, geographical, economic and national factors. Data from different countries should be interpreted with caution when applied to the individual patient. Patients rarely seek help for benign prostatic obstruction (BPO) unless urinary retention occurs,...‘No Deal’ Brexit – how might it impact urological practice in the UK?
On 29 March 2017, the Government of the United Kingdom of Great Britain & Northern Ireland triggered Article 50 of the Lisbon Treaty, formally starting the two-year period for talks with the European Union (EU) in which to reach a...
One cycle of adjuvant chemotherapy in tumours of the testis
Following a radical orchiectomy, current UK practice for newly diagnosed, high-risk, stage 1 nonseminomatous or combined germ cell tumours of the testis (NSCGCTT) is either two cycles of adjuvant chemotherapy with bleomycin, etoposide, cisplatin (BE360Px2) or surveillance with BE500Px3 on...
Renal fossa recurrence after nephrectomy for renal cell carcinoma
This paper is an analysis of 36 years of radical nephrectomy for renal cell carcinoma in the Mayo Clinic (1970-2006). In particular, it contains an analysis of the risk of renal fossa recurrence after nephrectomy (partial nephrectomies are not included)...
Vasectomy and prostate cancer
Urologists are always trying to identify risk factors for prostate cancer (CaP). This population-based study is from Ontario, Canada. The study sample comprised nearly 300,000 men who underwent vasectomy and an equal number who did not. The primary outcome was...
Tolerability and persistence in women prescribed mirabegron
Mirabegron is a beta-3 agonist used in the treatment of overactive bladder (OAB). Trials have shown reduced side-effects but equal efficacy when compared to anticholinergics. The authors wished to examine patients’ persistence with treatment, in a non-trial setting, over a...
The risk of failure after primary orchidopexy
Surgical standards for revalidation are growing in the UK. For paediatric surgery, primary orchidopexy is thought to be one procedure that could be used as a ‘plumb line’ for this. These authors looked at 1538 boys who underwent 1886 orchidopexies...
